Blanket disapproval of all unlicensed indications is wrong. by Evans, Stephen J
BEVACIZUMAB OFF-LABEL
Blanket disapproval of all unlicensed indications is
wrong
Stephen J Evans professor of pharmacoepidemiology
London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
“Off-label” covers a variety of situations. Applications for
marketing authorisations—licences that lead to a “label”—are
made by companies for almost entirely commercial reasons.
The company that makes bevacizumab does not apply for an
authorisation for use in macular degeneration because it also
makes the more expensive licensed product.
This is a failing of the licensing system, in that it relies on
companies to do things in the best interests of patients because
these usually coincide with their commercial interests. In this
situation, they do not.
The General Medical Council and Kyle mistakenly disapprove
of all unlicensed indications.1 If it were open (practically and
legally) to the NHS to apply for a marketing authorisation,
bevacizumab would probably become licensed for this
indication, but with pressure from companies and their allies to
prevent this, the opportunity to benefit more patients will be
lost.
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